A novel chordoma xenograft allows in vivo drug testing and reveals the importance of NF-κB signaling in chordoma biology.
Chordoma is a rare primary bone malignancy that arises in the skull base, spine and sacrum and originates from remnants of the notochord. These tumors are typically resistant to conventional chemotherapy, and to date there are no FDA-approved agents to treat chordoma. The lack of in vivo models of c...
Main Authors: | Matteo M Trucco, Ola Awad, Breelyn A Wilky, Seth D Goldstein, Ruili Huang, Robert L Walker, Preeti Shah, Varalakshmi Katuri, Naheed Gul, Yuelin J Zhu, Edward F McCarthy, Ido Paz-Priel, Paul S Meltzer, Christopher P Austin, Menghang Xia, David M Loeb |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3819300?pdf=render |
Similar Items
-
Rare Germline Variants in Chordoma-Related Genes and Chordoma Susceptibility
by: Sally Yepes, et al.
Published: (2021-05-01) -
Erlotinib inhibits growth of a patient-derived chordoma xenograft.
by: I-Mei Siu, et al.
Published: (2013-01-01) -
Sacral chordoma
by: M Behaeghe, et al.
Published: (2013-01-01) -
Clival chordoma
by: Tong HAN
Published: (2013-12-01) -
Clival chordoma in an infant.
by: Goel A, et al.
Published: (1996-04-01)